Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 5/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | PPARD | Q03181 | 4/20 | 0.39 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120342 | 0.89 | FFAR4 (0.48) | P2RX3FFAR4PPARGPTGDRFFAR1 | |
| SCHEMBL5106954 | 0.82 | PPARG (0.49) | P2RX3FFAR4PPARGFFAR1PTGER1 | |
| SCHEMBL5112547 | 0.79 | PPARG (0.46) | P2RX3FFAR4PPARGFFAR1CYP1A2 | |
| SCHEMBL5106677 | 0.77 | PPARG (0.51) | P2RX3FFAR4PPARGPTGDRFFAR1 | |
| SCHEMBL5109286 | 0.76 | PPARG (0.56) | P2RX3FFAR4PPARGFFAR1MRGPRX4 | |
| SCHEMBL5118952 | 0.74 | PPARG (0.47) | P2RX3FFAR4PPARGFFAR1MRGPRX4 | |
| SCHEMBL5118921 | 0.73 | MRGPRX4 (0.61) | FFAR4CYP1A2CYP2C9CYP2C19MRGPRX4 | |
| SCHEMBL5113860 | 0.73 | PPARG (0.52) | P2RX3FFAR4PPARGFFAR1 | |
| SCHEMBL5114324 | 0.72 | MAPT (0.44) | FFAR4PPARGFFAR1PTGER1CYP1A2 | |
| SCHEMBL5112205 | 0.72 | MAPT (0.43) | FFAR4PPARGFFAR1PTGER1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | P2RX3 746/4885FFAR4 91/4885PPARG 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.